{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:37:56Z","timestamp":1793367476720,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41585-026-01147-6","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:41Z","timestamp":1777374941000},"page":"702-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hot flushes during ADT for prostate cancer \u2014 a clinical rationale for a neurokinin 3 receptor antagonist"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-8226","authenticated-orcid":false,"given":"Martino","family":"Pedrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0093-8408","authenticated-orcid":false,"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"1147_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.yfrne.2013.07.003","volume":"34","author":"NE Rance","year":"2013","unstructured":"Rance, N. E., Dacks, P. A., Mittelman-Smith, M. A., Romanovsky, A. A. & Krajewski-Hall, S. J. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front. Neuroendocrinol. 34, 211\u2013227 (2013).","journal-title":"Front. Neuroendocrinol."},{"key":"1147_CR2","doi-asserted-by":"publisher","first-page":"19846","DOI":"10.1073\/pnas.1211517109","volume":"109","author":"MA Mittelman-Smith","year":"2012","unstructured":"Mittelman-Smith, M. A., Williams, H., Krajewski-Hall, S. J., McMullen, N. T. & Rance, N. E. Role for kisspeptin\/neurokinin B\/dynorphin (KNDy) neurons in cutaneous vasodilatation and the estrogen modulation of body temperature. Proc. Natl Acad. Sci. USA 109, 19846\u201319851 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1147_CR3","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1007\/s12325-021-01900-w","volume":"38","author":"SJ Menown","year":"2021","unstructured":"Menown, S. J. & Tello, J. A. Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review. Adv. Ther. 38, 5025\u20135045 (2021).","journal-title":"Adv. Ther."},{"key":"1147_CR4","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00403-023-02587-5","volume":"315","author":"M El-Samahy","year":"2023","unstructured":"El-Samahy, M. et al. Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials. Arch. Dermatol. Res. 315, 2215\u20132226 (2023).","journal-title":"Arch. Dermatol. Res."},{"key":"1147_CR5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0140-6736(17)30823-1","volume":"389","author":"JK Prague","year":"2017","unstructured":"Prague, J. K. et al. Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 389, 1809\u20131820 (2017).","journal-title":"Lancet"},{"key":"1147_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/GME.0000000000001510","volume":"27","author":"GL Fraser","year":"2020","unstructured":"Fraser, G. L. et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause 27, 382\u2013392 (2020).","journal-title":"Menopause"},{"key":"1147_CR7","doi-asserted-by":"publisher","first-page":"108220","DOI":"10.1016\/j.maturitas.2025.108220","volume":"195","author":"HM de Oliveira","year":"2025","unstructured":"de Oliveira, H. M. et al. Efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in postmenopausal women: a systematic review and meta-analysis. Maturitas 195, 108220 (2025).","journal-title":"Maturitas"},{"key":"1147_CR8","doi-asserted-by":"publisher","first-page":"174207","DOI":"10.1016\/j.ejphar.2021.174207","volume":"905","author":"A Tahara","year":"2021","unstructured":"Tahara, A., Takamatsu, H., Ohtake, A., Tanaka-Amino, K. & Kaku, S. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats. Eur. J. Pharmacol. 905, 174207 (2021).","journal-title":"Eur. J. Pharmacol."},{"key":"1147_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01486","author":"BJ Stish","year":"2026","unstructured":"Stish, B. J. et al. Alliance A222001: oxybutynin versus placebo for the treatment of hot flashes in patients receiving androgen-deprivation therapy for prostate cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-25-01486 (2026).","journal-title":"J. Clin. Oncol."},{"key":"1147_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa2415566","volume":"393","author":"F Cardoso","year":"2025","unstructured":"Cardoso, F. et al. Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer. N. Engl. J. Med. 393, 753\u2013763 (2025).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01147-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01147-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01147-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:01:43Z","timestamp":1793365303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01147-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1147"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01147-6","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"28 April 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.G. reports personal honoraria for advisory board roles for Sanofi, Orion, Roche, Amgen and MSD; honoraria from RSI (Televisione Svizzera Italiana); invited speaker roles for the European Society of Medical Oncology, the Swiss Group for Clinical Cancer Research, the Swiss Academy of Multidisciplinary Oncology, the Orikata Academy Research Group and the China Anti-Cancer Association Genitourinary Oncology Committee; a speaker bureau role for Janssen Cilag; a travel grant from ProteoMEdiX; institutional honoraria for advisory board roles for Bayer, Janssen Cilag, Roche and AAA International; independent data monitoring committee and steering committee roles for Amgen, Menarini Silicon Biosystems, Astellas Pharma, Tolero Pharmaceutcials, MSD, Pfizer, Telix Pharma, Bristol Myers Squibb and Orion; and a financial interest in patent WO2009138392 for a biomarker research method. P.B. reports advisory board and speaker roles for Bayer, Astellas, Ipsen, Janssen, AstraZeneca, Boston Scientific, Merck Serono, MSD and Neolys. B.T. reports financial relationships with Amgen Astellas, AstraZeneca, Bayer, Ferring, Janssens, Myovant, Novartis and MSD. M.P. reports a travel grant from Bayer.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}